Venous thromboembolism and cardiovascular risk: Results from the NAVIGATOR trial

American Journal of Medicine

Volumn 128, Issue 3, 2015, Pages 297-302

  Katz, Marcelo ^a,b   Califf, Robert M ^c   Sun, Jie Lena ^d   McMurray, John J V ^e   Thomas, Laine ^d   Lopes, Renato D ^d  

^a Brazilian Clinical Research Institute   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular; Outcomes; Venous thrombosis

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; NATEGLINIDE; PLACEBO; TRIACYLGLYCEROL; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; CYCLOHEXANE DERIVATIVE; PHENYLALANINE; TETRAZOLE DERIVATIVE; VALINE;

ADULT; ADVERSE OUTCOME; AGE; ANGINA PECTORIS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; DISEASE ASSOCIATION; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART DEATH; HEART FAILURE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; VENOUS THROMBOEMBOLISM; AGED; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; GLUCOSE INTOLERANCE; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARDIOVASCULAR DISEASES; CONFIDENCE INTERVALS; CYCLOHEXANES; FEMALE; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHENYLALANINE; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TETRAZOLES; TIME FACTORS; VALINE; VENOUS THROMBOEMBOLISM;

EID: 84924115639     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2014.08.022     Document Type: Article

References (22)

1. C. Becattini, G. Agnelli, and P. Prandoni A prospective study on cardiovascular events after acute pulmonary embolism Eur Heart J 26 1 2005 77 83
2. P. Prandoni, A. Ghirarduzzi, and M.H. Prins Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis J Thromb Haemost 4 9 2006 1891 1896
3. H.T. Sørensen, E. Horvath-Puho, and L. Pedersen Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: A 20-year cohort study Lancet 370 9601 2007 1773 1779
4. F.A. Klok, I.C. Mos, and L. Broek Risk of arterial cardiovascular events in patients after pulmonary embolism Blood 114 8 2009 1484 1488
5. C. Bova, A. Marchiori, and A. Noto Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study Thromb Haemost 96 2 2006 132 136
6. F.A. Spencer, J.S. Ginsberg, A. Chong, and D.A. Alter The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction J Thromb Haemost 6 9 2008 1507 1513
7. P. Prandoni, F. Bilora, and A. Marchiori An association between atherosclerosis and venous thrombosis N Engl J Med 348 15 2003 1435 1441
8. C. Hong, F. Zhu, and D. Du Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism Atherosclerosis 183 1 2005 169 174
9. C. Becattini, M.C. Vedovati, and W. Ageno Incidence of arterial cardiovascular events after venous thromboembolism: A systematic review and a meta-analysis J Thromb Haemost 8 5 2010 891 897
10. R.M. Califf, M. Boolell, and S.M. Haffner Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Am Heart J 156 4 2008 623 632
11. J.J. McMurray, R.R. Holman, and S.M. Haffner Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 16 2010 1477 1490
12. R.R. Holman, S.M. Haffner, and J.J. McMurray Effect of nateglinide on the incidence of diabetes and cardiovascular events N Engl J Med 362 16 2010 1463 1476
13. H. Krum, J.J. McMurray, and E. Horton Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials Cardiovasc Ther 28 2 2010 124 132
14. W. Ageno, C. Becattini, and T. Brighton Cardiovascular risk factors and venous thromboembolism: A meta-analysis Circulation 117 1 2008 93 102
15. P. Poredos, and M.K. Jezovnik In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction Heart Vessels 26 6 2011 596 602
16. E.M. Roumen-Klappe, M.C. Janssen, and J. Van Rossum Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: A prospective study J Thromb Haemost 7 4 2009 582 587
17. A.L. Rodriguez, B.M. Wojcik, and S.K. Wrobleski Statins, inflammation and deep vein thrombosis: A systematic review J Thromb Thrombolysis 33 4 2012 371 382
18. P. Gresele, S. Momi, and R. Migliacci Endothelium, venous thromboembolism and ischaemic cardiovascular events Thromb Haemost 103 1 2010 56 61
19. R. Migliacci, C. Becattini, and R. Pesavento Endothelial dysfunction in patients with spontaneous venous thromboembolism Haematologica 92 6 2007 812 818
20. G. Mazzoccoli, M. Grilli, and F. Ferrandino Arterial endothelial dysfunction and idiopathic deep venous thrombosis J Biol Regul Homeost Agents 25 4 2011 565 573
21. M.K. Jezovnik, P. Poredos, and M. Stalc Impairment of the vasodilatation capability of the brachial artery in patients with idiopathic venous thrombosis J Atheroscler Thromb 17 11 2011 1190 1198
22. J. Kassis, C. Neville, and J. Rauch Antiphospholipid antibodies and thrombosis: Association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis Thromb Haemost 92 6 2004 1312 1319